Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00176982
Status:
COMPLETED
Last Update Posted:
2009-08-13
First Post:
2005-09-12
Brief Title:
Plaquenil for Alopecia Areata Alopecia Totalis
Sponsor:
Hordinsky Maria K MD
Organization:
University of Minnesota
Study Overview
Official Title:
Open Label Study of Hydroxychloroquine for Alopecia Areata Alopecia Totalis
Status:
COMPLETED
Status Verified Date:
2009-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Alopecia areata is an autoimmune condition resulting in hair loss and complete baldness alopecia totalis Published evidence says that it is mediated by T-lymphocytes Plaquenil is an anti-inflammatory drug approved by the FDA for malaria lupus erythematosus and rheumatoid arthritis It has an effect on T-lymphocyte mediated inflammation making it a logical choice for a treatment trail for alopecia areata
Detailed Description:
Alopecia areata is a high prevalence autoimmune disease with significant consequences Alopecia areata is a tissue restricted autoimmune disease directed at the hair follicle resulting in hair loss Patients frequently suffer severe psychiatric consequences This is especially true of girls and young women who become bald The incidence of alopecia areata in the USA Minnesota is 202 per 100000 person-years with a lifetime risk of approximately 17 There is no significant gender difference The disease is often chronic with a remitting relapsing course Although it responds to immunosuppression generalized immunosuppression has significant morbidity and treatment is frequently frustrating and not successful New treatment options are essential With evidence that alopecia areata is a T-lymphocyte mediated autoimmune condition it has become a model system for the study of pathogenesis and treatment of T-cell mediated autoimmunity and as such is a model for a host of additional T-cell mediated autoimmune conditions
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None